The first-half results of ＡＤＲバイオメディカルホールディングス came in with a wider bottom-line loss. Detailed figures and the outlook are not explicitly stated in the article.
It has been reported that the first-half results of ＡＤＲバイオメディカルホールディングス came in with a wider bottom-line loss.
The article contains no explanation of the outlook for future performance, specific figures or underlying assumptions, and only indicates that the key point of the results was the widening loss.